Notice: Undefined index: HTTP_REFERER in D:\CNES\index.php on line 3
Lifitegrast Ophthalmic: Side Effects, Uses, Dosage, Interactions, Warnings

Lifitegrast Ophthalmic

Reviewed on 6/23/2023

What Is Lifitegrast Ophthalmic and How Does It Work?

Lifitegrast Ophthalmic is a prescription medication used to treat the signs and symptoms of dry eye disease (DED).

  • Lifitegrast Ophthalmic is available under the following different brand names: Xiidra

What Are Side Effects Associated with Using Lifitegrast Ophthalmic?

Common side effects of Lifitegrast Ophthalmic include:

  • eye irritation or discomfort
  • changes in taste
  • blurred vision

Serious side effects of Lifitegrast Ophthalmic include:

  • none

Rare side effects of Lifitegrast Ophthalmic include:

  • none 

Seek medical care or call 911 at once if you have the following serious side effects:

  • Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors;
  • Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;
  • Serious heart symptoms include fast, irregular, or pounding heartbeats; fluttering in the chest; shortness of breath; sudden dizziness, lightheadedness, or passing out.

This is not a complete list of side effects and other serious side effects or health problems that may occur as a result of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

What Are Dosages of Lifitegrast Ophthalmic?

Adult dosage

Ophthalmic solution

  • 5% (50mg/mL) in single-use containers

Dry Eye Disease

Adult dosage

  • Instill 1 drop every 12 hr into each eye 

Dosage Considerations – Should be Given as Follows: 

  • See “Dosages”

What Other Drugs Interact with Lifitegrast Ophthalmic?

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, healthcare provider, or pharmacist first.

  • Lifitegrast Ophthalmic has no noted severe interactions with other drugs
  • Lifitegrast Ophthalmic has no noted serious interactions with other drugs
  • Lifitegrast Ophthalmic has no noted moderate interactions with other drugs
  • Lifitegrast Ophthalmic has no noted minor interactions with other drugs

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist about all the products you use. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your healthcare professional or doctor for additional medical advice, or if you have health questions or concerns.

What Are Warnings and Precautions for Lifitegrast Ophthalmic?

Contraindications

  • Hypersensitivity to thedrug or excipients

Effects of drug abuse

  • None

Short-Term Effects

  • See “What Are Side Effects Associated with Using Lifitegrast Ophthalmic?”

Long-Term Effects

  • See “What Are Side Effects Associated with Using Lifitegrast Ophthalmic?”

Cautions

  • Patients should not touch the tip of the single-use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution
  • Advise patients that contact lenses should be removed prior to administration; lenses can be reinserted 15 minutes after administration
  • Advise patients that the solution from one single-use container is to be used immediately after opening; can be used to dose both eyes
  • Single-use containers, including any remaining contents, should be discarded immediately after administration

Pregnancy and Lactation

  • There are no available data regarding use in pregnant women to inform any drug-associated risks
  • Lactation
    • There are no data on the presence of lifitegrast in human milk; systemic exposure to the drug from ocular administration is low
References
https://reference.medscape.com/drug/xiidra-lifitegrast-ophthalmic-1000032